A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs.
OBJECTIVE
To investigate the effects of benazepril and heparin on renal function and blood pressure in dogs with chronic kidney disease.


METHODS
Randomized controlled clinical trial.


METHODS
26 dogs with chronic kidney disease.


METHODS
Dogs were randomly assigned to receive benazepril hydrochloride (0.5 mg/kg [0.23 mg/lb], PO, q 24 h; n = 10), benazepril and heparin (150 U/kg [68 U/lb], SC, q 8 h, for the first 6 days; 10), or a placebo (6) and were followed up for 180 days.


RESULTS
Health status score at the end of the study (ie, day 180) was significantly higher for dogs in the 2 treatment groups than for dogs in the placebo group. In addition, glomerular filtration rate was significantly increased and the urine protein-to-creatinine ratio was significantly decreased, compared with baseline rates, at the end of the study for dogs in both treatment groups but not for dogs in the placebo group. Systolic and diastolic blood pressures were significantly decreased on day 6 for dogs in both treatment groups.


CONCLUSIONS
Results suggested that administration of benazepril had beneficial effects in dogs with chronic kidney disease but that short-term administration of heparin in conjunction with benazepril did not appear to provide any additional benefit.
Tenhündfeld
Jörg
J
Small Animal Clinic, University of Veterinary Medicine, D-30173 Hanover, Germany.
Wefstaedt
Patrick
P
Nolte
Ingo J A
IJ
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D053099:Azotemia / Q000097:blood / Q000188:drug therapy / Q000662:veterinary; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count / Q000662:veterinary; D001774:Blood Chemical Analysis / Q000662:veterinary; D001794:Blood Pressure; D001806:Blood Urea Nitrogen; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D005260:Female; D006403:Hematologic Tests / Q000662:veterinary; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000000981:diagnostic imaging; D007674:Kidney Diseases / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D016896:Treatment Outcome; D014463:Ultrasonography; D016482:Urinalysis / Q000662:veterinary
D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D001552:Benzazepines; D006493:Heparin; D003404:Creatinine; C044946:benazepril